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Parkinson’s disease is a neurodegenerative disorder, which is characterized by the loss of dopaminergic neurons in substantia nigra. Also, it is observed the presence of cytoplasmic
inclusions (Lewy’s body or LB), made of α-synuclein, but also Lewy’s neurites (LN) formed by α-synuclein and ubiquitin. Despite environment play an important role in Parkinson
development, there are also some genetic factors that can imply Parkinson’s disease. These genetic features are assembled in two groups, α-synuclein and recessive genes (parkin, DJ-1
and PINK1). In this context, gene therapy has become in one of the most interesting fields due to the possibility to transfer corrected genes in affected cells or prevent cell death and
stimulate dopaminergic neuronal proliferation. In this context, high efficiency and security of viral vectors make these the main alternative for delivery.
THERAPY VECTOR PHASE ADMINISTRATION DA SURVIVAL UPDR IMPROVEMENT
GAD [4] AAV2 Phase 2 
Bilaterally injected into the 
STN
- 8,1 points 
AADC [5] AAV2 Phase 1
Bilaterally injected into the 
putamen
56% 30-46%
AADC/TH/GCH 
[6]
AAV and LV Preclinical Injected into the striatum - 60%
NRTN [7] AAV2 Phase 2 
Bilaterally injection into the 
putamen
62% 88%
GDNF [8] Ad, LV and AAV2 Preclinical Injected into the striatum 48,70% -
VEGF [9] AAV2 Preclinical Injected into the striatum - -
NURR1/FOXA2 
[10]
AAV2 and LV Preclinical
Injected into the 
peritoneum
69% -
INTRODUCTION
VIRAL VECTORS
ACTUAL APPROACHES 
CONCLUSION REFERENCES
Adenoviral vectors [1] Lentiviral vectors [2] Adenoassociated vectors [3]
 Non-enveloped, icosahedral, DNA
 Structural proteins: hexon, penton and fibre, IIIa, VI, 
VIII and IX (small proportion)
 4,5-30 kb DNA packaging capacity
 Immunogenic
 Long-term episomal expression
 Different generations: less viral content on genome 
 Endosomal trafficking 
 Enveloped, spherical, RNA
 Structural proteins: gag, pol, and env
 Other proteins: rev, tat (regulatory), vpu, vpr, vif and 
nef (accessory).
 7-12 kb DNA packaging capacity
 Long-term integrated expression
 Different generations: LTR and U3 modified, viral 
genes elimination
 RNA released on cytoplasm
 Non-enveloped, icosahedral, DNA
 Structural proteins: VP1, VP2 and VP3
 4,7 kb DNA packaging capacity
 Multiple serotypes (AAV1-12) and tropism
 Low immunogenicity and non-pathogenic
 Long-term episomal expression
 Endosomal trafficking
 Vector generation: rep and cap substitution by 
transgene
Most of the studied genes code for neurotrophic factors that either promote
neuroprotection or induce neuron growth, but also genes that code for different
enzymes involved in dopamine synthesis. AAV-based vectors, which are non-
pathogenic and non-immunogenic, are the most used vectors, also due to high
neuron tropism.
 Every therapy showed an evident improvement in Parkinson’s symptoms
and neuronal characteristics.
 Any problem derived from viral vectors was observed.
 AAV2 are the most employed vectors.
Ad-based vectors generations. Alba, R., a Bosch, and M. Chillon. 2005. “Gutless Adenovirus: Last-Generation
Adenovirus for Gene Therapy.” Gene therapy 12 Suppl 1:S18–27.
Lentiviral plasmid. Froelich, Steven, April Tai, and Pin Wang. 2010. “Lentiviral Vectors for Immune Cells
Targeting.” 32(2):208–18.
AAV.-based vectors production. Kotterman, Melissa A and David V Schaffer. 2014. “Engineering Adeno-
Associated Viruses for Clinical Gene Therapy.” Nature reviews. Genetics 15(7):445–51.
1. Prevention of neurodegeneration
2. Improvement of symptoms: tremor and dyskinesia
3. Higher production of dopamine
4. High safety of vectors: AAVs as the best vectors
5. Modest results
6. Possible upgrades: different or new vectors or other 
administration via
7. Potential therapy
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Comparative resume of different therapies trails developed 
Global rating of parkinsonism (a question from the brief parkinsonism
rating scale) showed a signiﬁcant diﬀerence between groups on a phase II
AAV2-GAD trial. LeWitt, Peter a. et al. 2011. “AAV2-GAD Gene Therapy for
Advanced Parkinson’s Disease: A Double-Blind, Sham-Surgery Controlled,
Randomised Trial.” The Lancet Neurology 10(4):309–19.
Mean change from baseline in the subgroup of patients of a phase 2
clinical trial of AAV2-NRTN therapy. Marks, William J. et al. 2010. “Gene
Delivery of AAV2-Neurturin for Parkinson’s Disease: A Double-Blind,
Randomised, Controlled Trial.” Lancet neurology 9(12):1164–72.
Changes in UPDRS scores in a phase 1 clinical trial of AAV2-AADC. Absolute
changes in scores from baseline to 6 months for individual patients. OFF, off-
medication state; ON, on-medication state; UPDRS, Unified Parkinson’s Disease
Rating Scale. Muramatsu, Shin-Ichi et al. 2002. “Recombinant Adeno-Associated
Viral Vectors Bring Gene Therapy for Parkinson’s Disease Closer to Reality.” Journal
of neurology 249 Suppl :II36–I40
mDA neurons in the cultures transduced with Nurr1 and/or Foxa2. The mDA
neuron–glia cultures were transduced with lentiviruses expressing Nurr1 (N), Foxa2
(F), Nurr1 + Foxa2 (NF), or control (C) and treated with the toxin for 8 h. Oh, Sang-
min et al. 2015. “Combined Nurr 1 and Foxa 2 Roles in the Therapy of Parkinson’s
Disease.” 1–17.
